FDA Approves Revolutionary Cell Therapy for Type 1 Diabetes
The FDA has granted approval to Chicago-based CellTrans for its pancreatic islet cell therapy, known as Lantidra or donislecel, making it the first-ever cell therapy treatment option for certain patients with type 1 diabetes who struggle to maintain normal blood glucose levels despite intensive management. The therapy utilizes pancreatic cells from deceased donors.